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We read with great interest the letter from Tambyraja and
colleagues concerning our article “Percutaneous coil embolization
of post-catheterization arterial femoral pseudoaneurysms.1,2
These authors advocate use of human autologous thrombin
rather than coils. We agree with their point of view when they point
out the efficacy of thrombin injection in their hands. As noted in
our paper, thrombin injection is a good technique, easy to per-
form, typically well-tolerated, and inexpensive.3 To rule out the
risk for anaphylaxis4 and the theoretical risk for prion protein
transmission, use of human thrombin has recently been proposed.5
Human thrombin can be synthesized with recombinant DNA
technology, which is expensive, or with preparations from the
patient’s blood, as first described by Quamby et al.5 Whatever its
origin, thrombin treatment is not 100% safe, and it exposes the
patient to downstream embolization and peripheral acute isch-
emia. In the article by Quarmby et al5 concerning 10 patients
successfully treated with human autologous thrombin, one throm-
bus extending into the lumen of the superficial femoral artery
occurred after femoral pseudoaneurysm embolization.
In addition, use of human autologous thrombin depends on
hospital expertise. The preparation of human autologous throm-
bin from patient blood is theoretically feasible in a coagulation
laboratory with a staff trained to prepare sterile injectable solutions.
This is unusual in French coagulation laboratories. To optimize
the procedure, a decentralized coagulation laboratory must be
created close to the vascular unit, under the responsibility of a
biologist, with a class II hood facility, a centrifuge, and special
laboratory materials. All of these conditions are unusual in France,
even in university hospitals. Furthermore, these conditions are
totally absent in smaller medical facilities, which generally do not
have an on-site coagulation laboratory.
We believe that coil embolization remains, at least in our
hands, 100% safe insofar as risk for ischemia related to emboliza-
tion; there have been no such events in 38 cases thus far. Moreover,
it remains the indication of choice in large neck pseudoaneurysms.
In addition, coils are relatively inexpensive, about 30 Euros each
(IMWCE 35/38; Cook, Bjaeverskov, Denmark).
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